Actively Recruiting
Study Comparing FlexiOss4 Bone Biocomposite to Standard Care for Healing Acute Bone Defects in Adults
Led by Medical Inventi S.A. · Updated on 2026-02-12
80
Participants Needed
2
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy, safety, and long-term outcomes of FlexiOss4, a biocomposite device for bone regeneration, compared to the current standard of care in patients with primary acute trauma bone defects. This study aims to assess radiological and clinical results over a comprehensive care period. The follow-up evaluations will take place at 2 and 6 weeks, and 3, 6, 12, and 24 months to monitor progress and safety. Participants will receive either the FlexiOss4 biocomposite implant or an allogenic human bone graft as part of their orthopedic procedure. The study is randomized and double-blinded, involving multiple centers. Both treatment groups will undergo scheduled rehabilitation and clinical care to support bone healing and function. During the study, participants will attend follow-up visits for physical examinations, X-rays, and blood tests to monitor calcium and phosphate levels. Researchers will assess load-bearing capacity, limb mobility, quality of life using the SF-36 questionnaire, and patient-reported outcomes with the LEFS scale. Safety will be closely tracked by recording adverse events up to 24 months. The total participation period spans two years, ensuring thorough long-term evaluation.
CONDITIONS
Brief Title
FlexiOss® - Efficacy, Safety and Long-term (Radiological and Clinical) Outcomes During Comprehensive Care Continuum of Implanted Biocomposite for Bone Regeneration.
Research Team
A
Anna Kasprzak-Czelej, PhD
B
Biuro Medical Inventi
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here